Dupixent approved in the US as the first-ever biologic medicine …
Sep 27, 2024 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Press Release: Dupixent is the first and only biologic to ... - Sanofi
Sep 11, 2005 · Dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease. If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European Union. …
Press Release: Dupixent approved in the US as the first-ever ... - Sanofi
Sep 27, 2013 · In July 2024, Sanofi and Regeneron announced that the European Medicines Agency approved Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils.
Press Room - Sanofi US News
Sep 11, 2024 · A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines.
Press Release: Dupixent® significantly reduced COPD ... - Sanofi
Nov 27, 2006 · The second Dupixent ® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly reduced (34%) exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.
Press Room - Sanofi US News
Mar 23, 2023 · The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial. Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with ...
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a …
5 days ago · Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight PR Newswire Tue, Nov 12, 2024, 5:31 PM 10 ...
Sanofi & Regeneron Drug Dupixent Gets EMA Approval as ... - MedCity News
Jul 7, 2024 · A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first biologic therapy approved for COPD driven by one particular type of inflammation.
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
Nov 7, 2024 · SNY. REGN. The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one. The approval extends the use ...